1-8 of 8
Jorge Nieva
Close
Sort by
Journal Articles

Significant Activity of Dasatinib in CLL Demonstrated by Ex-Vivo Assay.

Darren S. Sigal, MD, Jorge Nieva, MD, Jonathan Diver, PhD, Elisa Romeo, PhD, Francis Lee, PhD, Alan Saven, MD
Journal: Blood
Blood (2007) 110 (11): 4197.
https://doi.org/10.1182/blood.V110.11.4197.4197
Published: 2007
Journal Articles

Long-Term Dosing of AMG 531 in Thrombocytopenic Patients with Immune Thrombocytopenic Purpura: 48-Week Update.

David Kuter, James Bussel, James George, Louis Aledort, Alan Lichtin, Roger Lyons, Jorge Nieva, Jeffrey Wasser, Emanuelle Bourgeois, Mies Kappers-Klunne, Francois Lefrere, Martin Schipperus, Reggie Kelly, Jenny Christal, Matthew Guo, Janet Nichol
Journal: Blood
Blood (2006) 108 (11): 476.
https://doi.org/10.1182/blood.V108.11.476.476
Published: 2006
Journal Articles

Measurement of Blood-Borne Tissue Factor Procoagulant Activity in Healthy Individuals and Cancer Patients Using a Novel Assay.

Rachel E. Tilley, PhD, Todd Holscher, BSc, Rajesh Belani, MD, Jorge Nieva, MD, Nigel Mackman, PhD
Journal: Blood
Blood (2005) 106 (11): 1938.
https://doi.org/10.1182/blood.V106.11.1938.1938
Published: 2005
Journal Articles

Long-Term Dosing of AMG 531 Is Effective and Well Tolerated in Thrombocytopenic Patients with Immune Thrombocytopenic Purpura.

James B. Bussel, David J. Kuter, James N. George, Louis M. Aledort, Alan E. Lichtin, Roger M. Lyons, Jorge Nieva, Jeffrey S. Wasser, Emanuelle Bourgeois, Mies Kappers-Klunne, Francois LeFrere, Martin R. Schipperus, Reggie Kelly, Jenny Christal, Chien-Feng Chen, Janet L. Nichol
Journal: Blood
Blood (2005) 106 (11): 220.
https://doi.org/10.1182/blood.V106.11.220.220
Published: 2005
Journal Articles

Optophoresis Accurately Predicts Response to Chemotherapy in CLL.

Patricia McNeeley, B.S., Alan Saven, M.D., Ilona Kariv, Ph.D., Jorge Nieva, M.D., Philippe Marchand, Ph.D., Jonathan Diver, Ph.D., Samuel Riccitelli, M.S., Michael Nerenberg, M.D.
Journal: Blood
Blood (2004) 104 (11): 4834.
https://doi.org/10.1182/blood.V104.11.4834.4834
Published: 2004
Journal Articles

A Phase 2 Placebo Controlled Study Evaluating the Platelet Response and Safety of Weekly Dosing with a Novel Thrombopoietic Protein (AMG531) in Thrombocytopenic Adult Patients (pts) with Immune Thrombocytopenic Purpura (ITP).

David Kuter, MD, DPhil, James B. Bussel, MD, Louis M. Aledort, MD, James George, MD, Roger M. Lyons, MD, George T. Conklin, MD, Alan E. Lichtin, MD, Jorge Nieva, MD, Reggie Kelly, BA, Chien-Feng Chen, PhD, Janet L. Nichol, MS
Journal: Blood
Blood (2004) 104 (11): 511.
https://doi.org/10.1182/blood.V104.11.511.511
Published: 2004
Journal Articles

Patterns of Expression of SHP-1 and JAK-2p in Myelodysplastic Syndromes: A Potential New Prognostic Factor.

Armando V. Mena-Duran, M.D, Lyudmila A. Bazhenova, M.D., Summanuna Togo, Ph.D, Jose Cervera-Zamora, M.D., Kelly J. Bethel, M.D., Jorge Nieva, M.D., Alan Saven, M.D., Tomas Mustelin, M.D. Ph.D., Miguel A. Sanz, M.D. Ph.D
Journal: Blood
Blood (2004) 104 (11): 3430.
https://doi.org/10.1182/blood.V104.11.3430.3430
Published: 2004
Journal Articles

Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia

Clinical Trials & Observations
Jorge Nieva, Kelly Bethel, Alan Saven
Journal: Blood
Blood (2003) 102 (3): 810–813.
https://doi.org/10.1182/blood-2003-01-0014
Published: 2003